Equity is up >5% today following the release of a real-world study comparing Ozempic vs Trulicity (Eli Lilly)
• Novo reported a 23% reduced risk of heart attack, stroke and death in people with Type 2 diabetes on Medicare taking Ozempic vs dulaglutide (Trulicity).
• The real-world study involved 60,000 US Medicare patients (>=66yrs old).
• The equity is also benefiting from analyst upgrades following the recent appointment of a new CEO and the fact that the share-price is down 57% in 12 months so has room to revert higher.
Press Release: Link
Find more articles and bullets on these widgets:

| Type | 6-month bills |
| Maturity | Feb 19, 2026 |
| Amount | E1.082bln |
| Target | E1.1bln |
| Previous | E1.089bln |
| Avg yield | 1.947% |
| Previous | 1.923% |
| Bid-to-cover | 2.64x |
| Previous | 2.41x |
| Previous date | Jul 15, 2025 |